- Home
- RGNX vs BBNX Comparison
RGNX vs BBNX Comparison
Compare RGNX & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RGNX | BBNX |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | United States | United States |
| Employees | N/A | 423 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 528.6M | 493.1M |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | RGNX | BBNX |
|---|---|---|
| Price | $11.90 | $15.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 10 |
| Target Price | ★ $28.75 | $23.80 |
| AVG Volume (30 Days) | ★ 2.1M | 1.1M |
| Earning Date | 05-05-2026 | 04-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.08 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,393,000.00 | N/A |
| Revenue This Year | $51.21 | $34.90 |
| Revenue Next Year | $19.08 | $34.63 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 126.48 | N/A |
| 52 Week Low | $5.46 | $8.80 |
| 52 Week High | $16.19 | $32.71 |
Technical Indicators
Market Signals| Indicator | RGNX | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 79.66 | 62.69 |
| Support Level | $10.75 | $9.34 |
| Resistance Level | $12.05 | $32.52 |
| Average True Range (ATR) | 0.87 | 1.11 |
| MACD | 0.57 | 0.16 |
| Stochastic Oscillator | 96.16 | 64.78 |
Price Performance
Historical ComparisonAbout RGNX REGENXBIO Inc.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
About BBNX Beta Bionics Inc.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.